Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study
Brigham and Women's Hospital · Cardiovascular Events · Type2 Diabetes
Not applicable
Active, not recruiting
781,430
2026-05
Evidence dashboardStudies since 2006Updated Jul 31, 2026
AlbiglutideClinical Trials.
A source-linked view of every Albiglutide study in the current snapshot—status, phase, enrollment, results, publications, locations and changes over time.
- Total trials
- 39
- Recruiting
- 0
- Completed
- 31
- Terminated
- 3
- Results posted
- 24
- Average enrollment
- 540
- Countries
- 41
- Highest phase
- Phase 4
Largest indexed study
23,280,000 participants · NCT07188545 →Developer / research origin
GSK
Evidence summary
Activity is not efficacy.
Albiglutide appears in 39 indexed studies: 0 recruiting, 31 completed and 24 with registry results posted. The highest registered development stage in this snapshot is Phase 4. These counts measure registry activity; they do not establish that Albiglutide is safe or effective.
Review the design, endpoints, population, protocol changes, statistical analysis and publications before drawing conclusions.
Current studies
Recruiting or active
Completed studies
Finished records
Stopped studies
Withdrawn or terminated
NCT IDStudyPhase / statusEnrollmentUpdated
Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)
Ohio State University · Cardiovascular Kidney Metabolic Syndrome
Not applicable
Active, not recruiting
23,280,000
2025-09
NCT IDStudyPhase / statusEnrollmentUpdated
A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease
Janssen · Diabetes Mellitus, Type 2 · Cardiovascular Diseases
Not applicable
Completed
714,582
2025-06
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period
Sanofi · Type 2 Diabetes Mellitus
Phase 3
Completed
514
2022-03
Safety and Efficacy of Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine Subjects With Type 2 Diabetes Mellitus
GlaxoSmithKline · Diabetes Mellitus, Type 2
Phase 3
Completed
814
2020-11
Stepping-down Approach in Patients With Chronic Poorly-controlled Diabetes on Advanced Insulin Therapy?
University of California, San Francisco · Type 2 Diabetes Mellitus
Not applicable
Completed
22
2020-11
Albiglutide Versus Placebo in Insulin-treated Subjects With New-onset Type 1 Diabetes Mellitus
GlaxoSmithKline · Diabetes Mellitus, Type 1
Phase 2
Completed
67
2020-06
Safety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus
GlaxoSmithKline · Diabetes Mellitus, Type 2
Phase 3
Completed
308
2019-07
Showing 6 of 31 studies
NCT IDStudyPhase / statusEnrollmentUpdated
An Exploratory Study on the Effects of Repeat Doses of Albiglutide Compared to Exenatide on Gastric Myoelectrical Activity and Gastric Emptying in Type 2 Diabetes Mellitus Subjects
GlaxoSmithKline · Diabetes Mellitus, Type 2
Phase 4
Terminated
4
2020-10
A Study Comparing the Effect of Albiglutide With Exenatide on Regional Brain Activity Related to Nausea in Healthy Subjects
GlaxoSmithKline · Diabetes Mellitus
Phase 4
Terminated
5
2020-10
Extension to Study 200952 to Evaluate the Long-term Safety, Tolerability and Pharmacodynamics of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus Subjects
GlaxoSmithKline · Diabetes Mellitus, Type 2
Phase 4
Terminated
8
2019-07
A Study to Evaluate Pharmacokinetics, Safety and Efficacy of Albiglutide in Pediatric Subjects With Type 2 Diabetes Mellitus
GlaxoSmithKline · Diabetes Mellitus, Type 2
Phase 3
Withdrawn
0
2019-01
Albiglutide Versus Placebo Added-on to Basal-Bolus Insulin Therapy in Subjects With Type 2 Diabetes Mellitus
GlaxoSmithKline · Diabetes Mellitus, Type 2
Phase 3
Withdrawn
0
2016-01
Full study index
Search Albiglutide trials.
Add status, phase, condition, country, result and publication filters inside this molecule’s indexed study set.
39 matching studies
Last registry update first
Latest publications
Follow the paper trail.
PMID 35332216 ↗Kuruvilla DE, Mann JI, Tepper SJ, Starling AJ, Panza G, Johnson MAL. Phase 3 randomized, double-blind, sham-controlled Trial of e-TNS for the Acute treatment of Migraine (TEAM). Sci Rep. 2022 Mar 24;12(1):5110. doi: 10.1038/s41598-022-09071-6.Linked from NCT02787551PMID 35257461 ↗Ferrannini E, Niemoeller E, Dex T, Servera S, Mari A. Fixed-ratio combination of insulin glargine plus lixisenatide (iGlarLixi) improves ss-cell function in people with type 2 diabetes. Diabetes Obes Metab. 2022 Jun;24(6):1159-1165. doi: 10.1111/dom.14688. Epub 2022 Mar 28.Linked from NCT02787551PMID 34894329 ↗Guja C, Giorgino F, Blonde L, Ali A, Prazny M, Meier JJ, Souhami E, Lubwama R, Ji C, Rosenstock J. Concomitant iGlarLixi and Sodium-Glucose Co-transporter-2 Inhibitor Therapy in Adults with Type 2 Diabetes: LixiLan-G Trial and Real-World Evidence Results. Diabetes Ther. 2022 Jan;13(1):205-215. doi: 10.1007/s13300-021-01180-1. Epub 2021 Dec 11.Linked from NCT02787551PMID 33468520 ↗Blonde L, Rosenstock J, Frias J, Birkenfeld AL, Niemoeller E, Souhami E, Ji C, Del Prato S, Aroda VR. Durable Effects of iGlarLixi Up to 52 Weeks in Type 2 Diabetes: The LixiLan-G Extension Study. Diabetes Care. 2021 Mar;44(3):774-780. doi: 10.2337/dc20-2023. Epub 2021 Jan 19.Linked from NCT02787551PMID 31530665 ↗Blonde L, Rosenstock J, Del Prato S, Henry R, Shehadeh N, Frias J, Niemoeller E, Souhami E, Ji C, Aroda VR. Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial. Diabetes Care. 2019 Nov;42(11):2108-2116. doi: 10.2337/dc19-1357. Epub 2019 Sep 17.Linked from NCT02787551PMID 32694215 ↗Rosenstock J, Nino A, Soffer J, Erskine L, Acusta A, Dole J, Carr MC, Mallory J, Home P. Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial. Diabetes Care. 2020 Oct;43(10):2509-2518. doi: 10.2337/dc19-2316. Epub 2020 Jul 21.Linked from NCT02229227PMID 27222560 ↗Herman WH, Kalyani RR, Wexler DJ, Matthews DR, Inzucchi SE. Response to Comment on American Diabetes Association. Approaches to Glycemic Treatment. Sec. 7. In Standards of Medical Care in Diabetes-2016. Diabetes Care 2016;39(Suppl. 1):S52-S59. Diabetes Care. 2016 Jun;39(6):e88-9. doi: 10.2337/dci16-0003. No abstract available.Linked from NCT02846233PMID 26731084 ↗Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, DeFronzo RA, Einhorn D, Fonseca VA, Garber JR, Garvey WT, Grunberger G, Handelsman Y, Henry RR, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Rosenblit PD, Umpierrez GE; American Association of Clinical Endocrinologists (AACE); American College of Endocrinology (ACE). CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2016 EXECUTIVE SUMMARY. Endocr Pract. 2016 Jan;22(1):84-113. doi: 10.4158/EP151126.CS. No abstract available.Linked from NCT02846233
Related pages
Keep researching Albiglutide.
Commercial research listings, where present, are kept separate from clinical evidence and are not treatment recommendations.